Kira Peikoff (New York Times)
Another perspective related to the 23AndMe saga and why FDA has concerns.
Never mind how many, feel the sales potential – the Class of 2013 FDA Approvals
Drug Baron (TCP Innovations)
A look at the 2012 and 2013 classes of FDA-approved drugs.
Love or Hate Mutant Cereal, GMO-Free Cheerios Are an Empty Gesture
Marcus Wohlsen (Wired)
Succinct look at why this big story is really mostly a non-story.
Bad Statistics, and Bad Training, Are Sabotaging Drug Discovery
Stewart Lyman (Xconomy)
Why drugs are expensive: It’s the science, stupid.
Ashutosh Jogelekar (Scientific American)
Part One of a series.